Premium
Biological Properties of Salmon Calcitonin IV
Author(s) -
Schecroun Nadia,
Pidoux Elisabeth,
Horne William C.,
HernandezLagunas Laura,
Baron Roland,
Cressent Michele
Publication year - 1999
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1359/jbmr.1999.14.8.1425
Subject(s) - calcitonin , in vitro , receptor , antigenicity , potency , bioassay , bone resorption , biological activity , resorption , chemistry , pharmacology , salmon calcitonin , medicine , endocrinology , biology , biochemistry , immunology , antibody , genetics
In this study we characterized the biological activity of the recently identified salmon calcitonin (sCT) IV, in order to evaluate its potential therapeutic value. In the rat bioassay, sCT IV exhibited a 30% higher hypocalcemic activity than sCT I. The capacity of the molecule to inhibit bone resorption was assessed in vitro by the bone resorbing assay and the pit assay. An inhibitory effect, similar to that of sCT I, was observed in both assays. The interaction of sCT IV with the rabbit CT receptor was also studied. The affinity of sCT IV for the receptor was similar to that of sCT I, as was the potency for stimulating cAMP production. The antigenicity of the two molecules was not identical. Thus, this new CT could represent a useful novel therapeutic agent for the treatment of bone disorders.